Nausea on GLP-1 medications

Where nausea appears in the labels

Section 6.1 of each prescribing information, “Clinical Trials Experience”, has a table of reactions that were more common on the medicine than on placebo. Nausea is its first row in the labels for Ozempic®, Wegovy®, Mounjaro® and Zepbound®. Each label also has a section 5 warning called “Severe Gastrointestinal Adverse Reactions”, and each Medication Guide, the patient leaflet, lists nausea among the most common side effects ^{[1][2][3][4][5][6]}.

Section 6.1 also warns that rates from one medicine’s trials cannot be directly compared with another’s and may not match everyday practice. The figures below describe trial groups, not your personal odds.

Trial rates against placebo

These figures come from each label’s main placebo-controlled pool. The placebo column matters: some people reported nausea without receiving the medicine at all. Ranges cover a label’s dose groups.

What the European and Canadian product information adds

The European Medicines Agency sorts side effects into frequency classes rather than single percentages. “Very common” means at least 1 person in 10. Nausea is in that class in the product information for Ozempic®, Wegovy® and Mounjaro® ^[7][8][9]. There is no European Zepbound® listing: in the EU, tirzepatide is sold only as Mounjaro®, for both diabetes and weight management.

Each document also gives figures from its own trial pools, which is why the numbers differ slightly from the US table.

Vomiting and the wider stomach picture

Vomiting is counted separately. In the US pools it was reported by 5% to 9.2% on Ozempic® (2.3% on placebo), 24% on Wegovy® (6%), 5% to 9% on Mounjaro® (2%) and 8% to 13% on Zepbound® (2%). Counting every stomach and bowel reaction together, the Wegovy® label reports them in 73% of treated adults versus 47% on placebo, and the Zepbound® label in 56% versus 30% ^[2][5].

In a cardiovascular outcomes trial of adults with type 2 diabetes, the Mounjaro® label lists nausea at 17% and vomiting at 12% among the reactions that stood out from its usual safety picture ^[3].

When it tends to happen and how long it lasts

The labels tie nausea to dose increases. The Ozempic® label says most nausea, vomiting and/or diarrhea occurred during dose escalation; the Mounjaro® and Zepbound® labels say the same and add that these events decreased over time. The Wegovy® label says they were most frequent during dosage escalation ^[1][2][3][5].

The US labels give no duration. The European Wegovy® information does: across its trials, the median bout of nausea lasted 8 days and vomiting 2 days. A median means half of the bouts were shorter and half longer, so it is not a promise for any one person ^[8].

For some people it was enough to stop: 3.1% to 3.8% on Ozempic® stopped because of stomach reactions (0.4% on placebo), and 1.9% to 4.3% on Zepbound® (0.5%). In the Wegovy® weight trials, 1.8% stopped because of nausea itself, against 0.2% on placebo ^[1][2][5].

What a large trial analysis found

Researchers pooled the STEP 1, 2 and 3 trials of semaglutide 2.4 mg, with 2,117 people on the medicine and 1,262 on placebo over 68 weeks. Nausea was reported by 43.9% versus 16.1%. Of all stomach and bowel events on semaglutide, 99.5% were non-serious and 98.1% mild to moderate; most were transient and came during or shortly after a dose increase ^[11].

The analysis also asked whether people who felt sick lost more weight. They did not, in any meaningful way: weight loss was similar with or without stomach side effects, and less than 1 percentage point of the extra weight loss was explained by them. The study was funded by the manufacturer and looked at one medicine, so it says nothing directly about tirzepatide ^[11].

Why it may happen

What the labels support: all four US labels state that the medicine delays gastric emptying, meaning food leaves the stomach more slowly. For tirzepatide the labels add that this delay is largest after the first dose and becomes smaller over time ^[1][2][3][5]. The European Wegovy® information also describes semaglutide acting on brain areas, including the brainstem, that regulate food intake ^[8].

What is proposed but not measured in the labels: none of them says that slower emptying or these brain effects are what cause the nausea. The link is plausible, but the labels report how often nausea happened, not why.

General medical background: MedlinePlus lists slow stomach emptying among the common causes of nausea, and names the glutide family of diabetes and obesity medicines among the medicines that can bring it on ^[12].

What else could it be

Nausea has many causes that have nothing to do with a GLP-1 medicine. MedlinePlus lists stomach infections and food poisoning, reflux, migraine, pregnancy, motion sickness, severe pain such as from kidney stones, heavy cannabis use and other medicines. It also names more serious conditions in which nausea can be an early sign, such as appendicitis, a blocked bowel and stomach ulcers ^[12].

Within the labels themselves, nausea also appears as part of two warnings that are not ordinary side effects: inflammation of the pancreas and gallbladder problems. That is why the pain and other signs that come with nausea matter as much as the nausea.

What may help

The Medication Guides give one practical tip: drinking fluids helps lower the chance of dehydration ^[2][4][6]. For other measures, the manufacturers’ own patient pages are more specific.

• Novo Nordisk’s Wegovy® page suggests eating more slowly, choosing bland, low-fat foods such as crackers, toast and rice, and foods that contain water such as soups and gelatin, getting fresh air, and avoiding greasy food and lying down after eating ^[13].
• Eli Lilly’s Zepbound® page suggests splitting meals into smaller ones, stopping when you feel full, avoiding fatty foods and trying bland foods ^[14].
• MedlinePlus advises drinking small amounts of clear liquids often while you are being sick ^[12].
• Medicines for nausea, including over-the-counter ones, are a question for your prescriber or pharmacist. The Wegovy® page reminds readers that the medicine slows stomach emptying, which may matter for tablets that are meant to move through the stomach fast ^[13].

Fluids and the kidney warning

Section 5 of each label carries a warning about acute kidney injury due to volume depletion. The labels say most of the reported cases happened in people whose stomach reactions, such as nausea, vomiting or diarrhea, led to dehydration, and that kidney function should be monitored in people reporting those reactions, especially when treatment starts and when the dose goes up ^[1][2][3][5].

MedlinePlus lists the usual signs of dehydration: a dry mouth, more thirst, passing urine less often or dark yellow urine, and sunken eyes ^[12].

What to write down

Nausea is easier to discuss with a pattern attached: when it started, how many days after your injection, how long it lasted, whether it came before or after a meal and which meal, whether you vomited, and roughly how much you drank. Note whether it was the first week on a new dose, the period the labels point to.

A few weeks of notes can show whether nausea clusters on certain days after a dose, follows particular meals or is easing. Your clinician can work with that; a vague memory of feeling sick a lot is harder to act on.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.